Μπορείτε να στέλνετε ειδήσεις και Δελτία Τύπου στο email μας.
Αν θέλετε να επικοινωνήσετε μαζί μας ή να στείλετε Δελτίο Τύπου πατήστε εδώ...pharmamarketingexpertsblog@gmail.com


Τετάρτη 11 Απριλίου 2012

A more ‘nimble approach’ needed for CRO-pharma partnerships


InPharm | Ben Adams 

Pharma firms need to create closer and more flexible relationships with their contract research organisations for better outcomes.

This is according to a new report: ‘Nimble Partnerships in the Pharma Industry: Well-Designed CRO Relationships Enhance Focus and Flexibility’, commissioned by ICON, a provider of outsourced development services to the pharma industry, and the global consulting firm Booz & Company.  

ICON says that pharma companies are increasingly using contract research organisation (CROs) to undertake their research and development, and their study provides new insight into how to structure the relevant partnerships for success.

The key findings of the report shows that CROs need to demonstrate innovative approaches in activities that range from monitoring to data-driven insights to employee retention.
The report also says that pharma companies that adopt a nimble, capability-centred approach to partnerships will be more focused, make better use of their distinct capabilities, and generate more value.

Global pharmaceutical outsourcing is expected to reach $28 billion this year and climb to $35.5 billion by 2015, an increase of more than 10% since 2009.

“Developing the capabilities to partner with CROs is a critical key to success for pharma companies in today’s increasingly complex and competitive environment,” said Matthew Le Merle, a partner with Booz & Company. “But our research clearly showed that most companies are not structuring their CRO relationships strategically. This is wasting time and money they can ill afford to lose.”
Ciaran Murray, chief executive at ICON, said: "Regardless of the model chosen, a top-down approach to partnerships where the performance measures are tied to the strategic objectives of the partnership is fundamental to success.

“ICON has been successful in building close strategic partnerships by being flexible and innovative in the way that we conduct clinical research and in how we build our partnerships.
“We also continuously look to expand our capabilities and service offerings in order to ensure that we deliver value,” he added.